M

Myriad Genetics
D

MYGN

12.270
USD
-0.30
(-2.39%)
مغلق
حجم التداول
20,853
الربح لكل سهم
0
العائد الربحي
-
P/E
-10
حجم السوق
1,117,002,272
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    BDX
    BDX
    -2.330
    (-0.97%)
    237.930 USD
    D
    DGX
    -1.120
    (-0.73%)
    151.530 USD
    H
    HOLX
    0.785
    (1.12%)
    71.145 USD
    ILMN
    ILMN
    -1.005
    (-0.71%)
    140.300 USD
    L
    LH
    -1.660
    (-0.68%)
    242.340 USD
    TMO
    TMO
    1.41
    (0.25%)
    574.31 USD
    المزيد
الأخبار
المقالات

العنوان: Myriad Genetics

القطاع: Healthcare
الصناعة: Diagnostics & Research
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarkerdiscovery and companion diagnostic services to pharma and biotech companies.